1Clara LMY, Richard F, Cecelia LWC, et al . Measuring quality of life of chinese cancer patients: a validation of the chinese version of the functional assessment of cancer therapy-general (FACT-G) scale.Cancer, 2000,88:1715.
2Liepe K,Franke WG,Kropp J,et al.Comparison of rhenium-188,rhenium-186-HEDP and strontium-89 in palliation of painful bone metastases[J].Nuklearmedizin,2000,39(6):146-151.
3Magnetto S,Boissier S,Delmas PD,et al.Additive antitumor activities of taxoids in combination with the bisphosphonate ibandronate against invasion and adhesion of human breast carcinoma cells to bone [J].Int J Cancer,1999,83 (2) :263-269.
4Hiraga T,Williams PJ,Mundy GR,et al.The bisphosphonate ibandronate promotes apoptosis in MDA-MB-231 human breast cancer cells in bone metastases [J].Cancer Res,2001,61 (11):4418-4424.
5Coleman RE.Efficacy of zoledronic acid and pamidronate in breast cancer patients:a comparative analysis of randomized phase Ⅲ trails[J].Am J Clin Oncol,2002,25(6 Suppl 1) :25-31.
6Rosen LS,Gordon D,Tchekmedyian S,et al.Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors:a phase Ⅲ,double blind,randomized trail - The Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group [J].J Clin Oncol,2003,21 (16):3150-3157.
7Body JJ.Reducing skeletal complications and bone pain with intravenous ibandronate for metastatic bone disease [J].EJC Supplements ,2004,2(5) :5-8.
8Leyland-Jones B.Pharmacokinetic and clinical equivalence of oral and intravenous ibandronate for metastatic bone disease[J].EJC Supplements ,2004,2(5) :9-12.
9Diel IJ.Ibandronate:a well -tolerated intravenous and oral treatment for metastatic bone disease[J].EJC Supplements,2004,2(5) :13-16.
10Quint LE,Tummala S,Bressin LJ,et al.Distribution of distant metastases from newly diagnosed non-small-cell lung cancer [J].Ann Thorac Surg,1996,62(1) :246-250.
